Sweden's Klaria net loss narrows on lower R&D expenses

Klaria Pharma Holding AB (publ)

31/08/2026 23:08

Overview
Sweden pharma developer reported no Q2 net sales, unchanged from prior year
Q2 net loss after tax narrowed year-over-year, with lower R&D expenses
Operating cash flow widened and liquid assets increased from last year

Outlook
Klaria did not provide specific guidance or outlook for future periods

Result Drivers
LOWER R&D EXPENSES - Klaria attributed narrowed net loss after tax to reduced R&D expenses in Q2

Company press release: ID:nWkr7dst7D

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 0
 
Q2 Loss Per Share
 
SEK 0.05
 
Q2 Net Loss After Tax
 
SEK 12.90 mln
 
Q2 Cash Flow from Operating Activities
 
-SEK 14.80 mln
 

Analyst Coverage
The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 30 three months ago

Reuters Recommended Reads
Aug 31 - Swedish drug developer DexTech's Q4 operating loss widens; reports positive patient outcomes
Aug 31 - China's Ascletis Pharma H1 net loss widens on higher R&D costs
Aug 31 - Israel's BioLineRx Q2 net loss widens on higher R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)